A glance over doxorubicin based-nanotherapeutics: from proof-of-concept studies to solutions in the market

Detalhes bibliográficos
Autor(a) principal: Gonçalves, Mara
Data de Publicação: 2020
Outros Autores: Mignani, Serge, Rodrigues, João, Tomás, Helena
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.13/3650
Resumo: Cancer is one of the leading causes of death worldwide and, as such, efforts are being done to find new che motherapeutic drugs or, alternatively, novel approaches for the delivery of old ones. In this scope, when used as vehicles for drugs, nanomaterials may potentially maximize the efficacy of the treatment and reduce its side effects, for example by a change in drug's pharmacokinetics, cell targeting and/or specific stimuli-responsive ness. This is the case of doxorubicin (DOX) that presents a broad spectrum of activity and is one of the most widely used chemotherapeutic drugs as first-line treatment. Indeed, DOX is a very interesting example of a drug for which several nanosized delivery systems have been developed over the years. While it is true that some of these systems are already in the market, it is also true that research on this subject remains very active and that there is a continuing search for new solutions. In this sense, this review takes the example of doxorubicin, not so much with the focus on the drug itself, but rather as a case study around which very diverse and imaginative nanotechnology approaches have emerged.
id RCAP_2afec3aa6e4432b0825f053e937c23e6
oai_identifier_str oai:digituma.uma.pt:10400.13/3650
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling A glance over doxorubicin based-nanotherapeutics: from proof-of-concept studies to solutions in the marketCancerChemotherapyDoxorubicinNanotherapeuticsDelivery systemsClinical trials.Faculdade de Ciências Exatas e da EngenhariaCentro de Química da MadeiraCancer is one of the leading causes of death worldwide and, as such, efforts are being done to find new che motherapeutic drugs or, alternatively, novel approaches for the delivery of old ones. In this scope, when used as vehicles for drugs, nanomaterials may potentially maximize the efficacy of the treatment and reduce its side effects, for example by a change in drug's pharmacokinetics, cell targeting and/or specific stimuli-responsive ness. This is the case of doxorubicin (DOX) that presents a broad spectrum of activity and is one of the most widely used chemotherapeutic drugs as first-line treatment. Indeed, DOX is a very interesting example of a drug for which several nanosized delivery systems have been developed over the years. While it is true that some of these systems are already in the market, it is also true that research on this subject remains very active and that there is a continuing search for new solutions. In this sense, this review takes the example of doxorubicin, not so much with the focus on the drug itself, but rather as a case study around which very diverse and imaginative nanotechnology approaches have emerged.ElsevierDigitUMaGonçalves, MaraMignani, SergeRodrigues, JoãoTomás, Helena2021-09-22T09:11:04Z20202020-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.13/3650engGonçalves, M., Mignani, S., Rodrigues, J., & Tomás, H. (2020). A glance over doxorubicin based-nanotherapeutics: from proof-of-concept studies to solutions in the market. Journal of Controlled Release, 317, 347-374. https://doi.org/10.1016/j.jconrel.2019.11.01610.1016/j.jconrel.2019.11.016info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-24T05:11:45Zoai:digituma.uma.pt:10400.13/3650Portal AgregadorONGhttps://www.rcaap.pt/oai/openairemluisa.alvim@gmail.comopendoar:71602024-03-24T05:11:45Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv A glance over doxorubicin based-nanotherapeutics: from proof-of-concept studies to solutions in the market
title A glance over doxorubicin based-nanotherapeutics: from proof-of-concept studies to solutions in the market
spellingShingle A glance over doxorubicin based-nanotherapeutics: from proof-of-concept studies to solutions in the market
Gonçalves, Mara
Cancer
Chemotherapy
Doxorubicin
Nanotherapeutics
Delivery systems
Clinical trials
.
Faculdade de Ciências Exatas e da Engenharia
Centro de Química da Madeira
title_short A glance over doxorubicin based-nanotherapeutics: from proof-of-concept studies to solutions in the market
title_full A glance over doxorubicin based-nanotherapeutics: from proof-of-concept studies to solutions in the market
title_fullStr A glance over doxorubicin based-nanotherapeutics: from proof-of-concept studies to solutions in the market
title_full_unstemmed A glance over doxorubicin based-nanotherapeutics: from proof-of-concept studies to solutions in the market
title_sort A glance over doxorubicin based-nanotherapeutics: from proof-of-concept studies to solutions in the market
author Gonçalves, Mara
author_facet Gonçalves, Mara
Mignani, Serge
Rodrigues, João
Tomás, Helena
author_role author
author2 Mignani, Serge
Rodrigues, João
Tomás, Helena
author2_role author
author
author
dc.contributor.none.fl_str_mv DigitUMa
dc.contributor.author.fl_str_mv Gonçalves, Mara
Mignani, Serge
Rodrigues, João
Tomás, Helena
dc.subject.por.fl_str_mv Cancer
Chemotherapy
Doxorubicin
Nanotherapeutics
Delivery systems
Clinical trials
.
Faculdade de Ciências Exatas e da Engenharia
Centro de Química da Madeira
topic Cancer
Chemotherapy
Doxorubicin
Nanotherapeutics
Delivery systems
Clinical trials
.
Faculdade de Ciências Exatas e da Engenharia
Centro de Química da Madeira
description Cancer is one of the leading causes of death worldwide and, as such, efforts are being done to find new che motherapeutic drugs or, alternatively, novel approaches for the delivery of old ones. In this scope, when used as vehicles for drugs, nanomaterials may potentially maximize the efficacy of the treatment and reduce its side effects, for example by a change in drug's pharmacokinetics, cell targeting and/or specific stimuli-responsive ness. This is the case of doxorubicin (DOX) that presents a broad spectrum of activity and is one of the most widely used chemotherapeutic drugs as first-line treatment. Indeed, DOX is a very interesting example of a drug for which several nanosized delivery systems have been developed over the years. While it is true that some of these systems are already in the market, it is also true that research on this subject remains very active and that there is a continuing search for new solutions. In this sense, this review takes the example of doxorubicin, not so much with the focus on the drug itself, but rather as a case study around which very diverse and imaginative nanotechnology approaches have emerged.
publishDate 2020
dc.date.none.fl_str_mv 2020
2020-01-01T00:00:00Z
2021-09-22T09:11:04Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.13/3650
url http://hdl.handle.net/10400.13/3650
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Gonçalves, M., Mignani, S., Rodrigues, J., & Tomás, H. (2020). A glance over doxorubicin based-nanotherapeutics: from proof-of-concept studies to solutions in the market. Journal of Controlled Release, 317, 347-374. https://doi.org/10.1016/j.jconrel.2019.11.016
10.1016/j.jconrel.2019.11.016
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv mluisa.alvim@gmail.com
_version_ 1817542901654093824